Stability Indicating Methods for Determination of Third Generation Antiepileptic Drugs and Their Related Substances

References

• World Health Organization. Epilepsy. https://www.who.int/news-room/fact-sheets/detail/epilepsy. (accessed Sept 13, 2020).
   Google Scholar
• Moshé, S. L.; Perucca, E.; Ryvlin, P.; Tomson, T. Epilepsy: New Advances. Lancet 2015, 385, 884–898. DOI: 10.1016/S0140-6736(14)60456-6.
   PubMed Web of Science ®Google Scholar
• Sills, G. J.; Rogawski, M. A. Mechanisms of Action of Currently Used Antiseizure Drugs. Neuropharmacology 2020, 168, 107913–107966. DOI: 10.1016/j.neuropharm.2020.107966.
   Web of Science ®Google Scholar
• Landmark, C. J.; Johannessen, S. I.; Patsalos, P. N. Therapeutic Drug Monitoring of Antiepileptic Drugs: Current Status and Future Prospects. Expert Opin. Drug Metab. Toxicol. 2020, 16, 227–238. DOI: 10.1080/17425255.2020.1724956.
   PubMed Web of Science ®Google Scholar
• Singh, K. P.; Verma, N. Teratogenic Potential of Third-Generation Antiepileptic Drugs: Current Status and Research Needs. Pharmacol. Rep. 2019, 71, 491–502. DOI: 10.1016/j.pharep.2019.01.011.
   PubMed Web of Science ®Google Scholar
• Patsalos, P.; Spencer, E.; Berry, D. Therapeutic Drug Monitoring of Antiepileptic Drugs in Epilepsy: A 2018 Update. Ther. Drug Monit. 2018, 40, 526–548. DOI: 10.1097/FTD.0000000000000546.
   PubMed Web of Science ®Google Scholar
• Maggio, R. M.; Vignaduzzo, S. E.; Kaufman, T. S. Practical and Regulatory Considerations for Stability-Indicating Methods for the Assay of Bulk Drugs and Drug Formulations. TrAC - Trends Anal. Chem. 2013, 49, 57–70. DOI: 10.1016/j.trac.2013.05.008.
   Web of Science ®Google Scholar
• Santulli, L.; Coppola, A.; Balestrini, S.; Striano, S. The Challenges of Treating Epilepsy with 25 Antiepileptic Drugs. Pharmacol. Res. 2016, 107, 211–219. DOI: 10.1016/j.phrs.2016.03.016.
   PubMed Web of Science ®Google Scholar
• de Biase, S.; Nilo, A.; Bernardini, A.; Gigli, G. L.; Valente, M.; Merlino, G. Timing Use of Novel anti-Epileptic Drugs: Is Earlier Better? Expert Rev. Neurother. 2019, 19, 945–954. DOI: 10.1080/14737175.2019.1636649.
   PubMed Web of Science ®Google Scholar
• Perucca, E.; Brodie, M. J.; Kwan, P. Tomson, T. 30 Years of Second-Generation Antiseizure Medications: Impact and Future Perspectives. Lancet Neurol. 2020, 4422, 1–12. DOI: 10.1016/s1474-4422(20)30035-1.
   Google Scholar
• Liu, D. Q.; Sun, M.; Kord, A. S. Recent Advances in Trace Analysis of Pharmaceutical Genotoxic Impurities. J. Pharm. Biomed. Anal. 2010, 51, 999–1014. DOI: 10.1016/j.jpba.2009.11.009.
   PubMed Web of Science ®Google Scholar
• International Conference Harmonisation Q3A (R2): Impurities in New Drug Substances, ICH Harmon. Tripart. Guidel, 2006.
   Google Scholar
• International Conference on Harmonisation. Q3B (R2): Impurities in New Drug Products. ICH Harmon. Tripart. Guidel, 2006.
   Google Scholar
• Jain, D.; Basniwal, P. K. Forced Degradation and Impurity Profiling: Recent Trends in Analytical Perspectives. J. Pharm. Biomed. Anal. 2013, 86, 11–35. DOI: 10.1016/j.jpba.2013.07.013.
   PubMed Web of Science ®Google Scholar
• EMA. Inovelon, Rufinamide. https://www.ema.europa.eu/en/medicines/human/EPAR/inovelon. (accessed Aug 17, 2020).
   Google Scholar
• FDA. Drugs@FDA: FDA-Approved Drugs. New Drug Application (NDA): 021911. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=021911. (accessed Aug 17, 2020).
   Google Scholar
• EMA. Diacomit, Stiripentol. https://www.ema.europa.eu/en/medicines/human/EPAR/diacomit. (accessed Aug 17, 2020).
   Google Scholar
• FDA. Drugs@FDA: FDA-Approved Drugs. New Drug Application (NDA): 206709. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206709. (accessed Aug 17, 2020).
   Google Scholar
• EMA. Vimpat, Lacosamide. https://www.ema.europa.eu/en/medicines/human/EPAR/vimpat. (accessed Aug 15, 2020).
   Google Scholar
• FDA. FDA. Drugs@FDA: FDA-Approved Drugs. New Drug Application (NDA): 022253. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022253. (accessed Aug 15, 2020).
   Google Scholar
• EMA. Zebinix, Esliscarbazepine Acetate. https://www.ema.europa.eu/en/medicines/human/EPAR/zebinix. (accessed Aug 15, 2020).
   Google Scholar
• FDA. FDA. Drugs@FDA: FDA-Approved Drugs. New Drug Application (NDA): 211199. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211199. (accessed Aug 15, 2020).
   Google Scholar
• EMA. Fycompa, Perampanel. https://www.ema.europa.eu/en/medicines/human/EPAR/fycompa. (accessed Aug 15, 2020).
   Google Scholar
• FDA. Drugs@FDA: FDA-Approved Drugs. New Drug Application (NDA): 208277. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=208277. (accessed Aug 15, 2020).
   Google Scholar
• EMA. Briviact, Brivaracetam. https://www.ema.europa.eu/en/medicines/human/EPAR/briviact-italy-nubriveo#authorisation-details-section. (accessed Aug 15, 2020).
   Google Scholar
• FDA. FDA. Drugs@FDA: FDA-Approved Drugs. New Drug Application (NDA): 205836. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=205836. (accessed Aug 15, 2020).
   Google Scholar
• EMA. Votubia, Everolimus. https://www.ema.europa.eu/en/medicines/human/EPAR/votubia. (accessed Aug 15, 2020).
   Google Scholar
• FDA. Drugs@FDA: FDA-Approved Drugs. New Drug Application (NDA): 022334. H https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022334. (accessed Aug 17, 2020).
   Google Scholar
• Rogawski, M. A.; Löscher, W.; Rho, J. M. Mechanisms of Action of Antiseizure Drugs and the Ketogenic Diet. Cold Spring Harb. Perspect. Med. 2016, 6, a022780–28. DOI: 10.1101/cshperspect.a022780.
   PubMed Web of Science ®Google Scholar
• Scifinder. https://scifinder.cas.org (acessed May, 2020).
   Google Scholar
• Pubchem. hppts://pubchem.ncbi.nlm.nih.gov/ (acessed May, 2020).
   Google Scholar
• Almeida, L.; Soares-da-Silva, P. Eslicarbazepine Acetate (BIA 2-093). Neurotherapeutics 2007, 4, 88–96. DOI: 10.1016/j.nurt.2006.10.005.
   PubMed Web of Science ®Google Scholar
• Hibi, S.; Ueno, K.; Nagato, S.; Kawano, K.; Ito, K.; Norimine, Y.; Takenaka, O.; Hanada, T.; Yonaga, M. Discovery of 2-(2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (perampanel): A Novel, Noncompetitive α-Amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid (AMPA) Receptor Antagonist. J. Med. Chem. 2012, 55, 10584–10600. DOI: 10.1021/jm301268u.
   PubMed Web of Science ®Google Scholar
• Perucca, E.; Cloyd, J.; Critchley, D.; Fuseau, E. Rufinamide: Clinical Pharmacokinetics and Concentration-Response Relationships in Patients with Epilepsy. Epilepsia 2008, 49, 1123–1141. DOI: 10.1111/j.1528-1167.2008.01665.x.
   PubMed Web of Science ®Google Scholar
• Trojnar, M. K.; Wojtal, K.; Trojnar, M. P.; Czuczwar, S. J. Stiripentol. A Novel Antiepileptic Drug. Pharmacol. Rep. 2005, 57, 154–160.
   PubMed Web of Science ®Google Scholar
• Czuczwar, S. J.; Trojnar, M. K.; Gergont, A.; Kroczka, S.; Kacinski, M. Stiripentol - Characteristic of a New Antiepileptic Drug. Expert Opin. Drug Discov. 2008, 3, 453–460. DOI: 10.1517/17460441.3.4.453.
   PubMed Web of Science ®Google Scholar
• Beyreuther, B. K.; Freitag, J.; Heers, C.; Krebsfänger, N.; Scharfenecker, U.; Stöhr, T. Lacosamide: A Review of Preclinical Properties. CNS Drug Rev. 2007, 13, 21–42. DOI: 10.1111/j.1527-3458.2007.00001.x.
   PubMedGoogle Scholar
• Rogawski, M. A.; Tofighy, A.; White, H. S.; Matagne, A.; Wolff, C. Current Understanding of the Mechanism of Action of the Antiepileptic Drug Lacosamide. Epilepsy Res. 2015, 110, 189–205. DOI: 10.1016/j.eplepsyres.2014.11.021.
   PubMed Web of Science ®Google Scholar
• Rocamora, R. A Review of the Efficacy and Safety of Eslicarbazepine Acetate in the Management of Partial-Onset Seizures. Ther. Adv. Neurol. Disord. 2015, 8, 178–186. DOI: 10.1177/1756285615589711.
   PubMed Web of Science ®Google Scholar
• Malawska, B.; Kulig, K. Brivaracetam: A New Drug in Development for Epilepsy and Neuropathic Pain. Expert Opin. Investig. Drugs 2008, 17, 361–369. DOI: 10.1517/13543784.17.3.361.
   PubMed Web of Science ®Google Scholar
• Qiu, S.; Tehrani, K. A.; Sergeyev, S.; Bultinck, P.; Herrebout, W.; Mathieu, B. Stereochemistry of the Brivaracetam Diastereoisomers. Chirality 2016, 28, 215–225. DOI: 10.1002/chir.22558.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency, E. Votubia, Everolimus. Comm. Med. Prod. Hum. Use. 2011, 44, 0–88.
   Google Scholar
• Jang, S. W.; Kang, M. J. Improved Oral Absorption and Chemical Stability of Everolimus via Preparation of Solid Dispersion Using Solvent Wetting Technique. Int. J. Pharm. 2014, 473, 187–193. DOI: 10.1016/j.ijpharm.2014.06.006.
   PubMed Web of Science ®Google Scholar
• Moraes do Carmo, A. C.; Pereira, R. S.; Gratieri, T. Brazilian Requirements for Stability Indicating Methods. TrAC - Trends Anal. Chem. 2018, 98, 58–63. DOI: 10.1016/j.trac.2017.10.017.
   Web of Science ®Google Scholar
• Sengupta, P.; Chatterjee, B.; Tekade, R. K. Current Regulatory Requirements and Practical Approaches for Stability Analysis of Pharmaceutical Products: A Comprehensive Review. Int. J. Pharm. 2018, 543, 328–344. DOI: 10.1016/j.ijpharm.2018.04.007.
   PubMedGoogle Scholar
• Ramachandra, B. Critical Reviews in Analytical Chemistry Development of Impurity Profiling Methods Using Modern Analytical Techniques. Crit. Rev. Anal. Chem. 2017, 47, 24–36. DOI: 10.1080/10408347.2016.1169913.
   PubMed Web of Science ®Google Scholar
• Zhang, K.; Kurita, K. L.; Venkatramani, C.; Russell, D. Seeking Universal Detectors for Analytical Characterizations. J. Pharm. Biomed. Anal. 2019, 162, 192–204. DOI: 10.1016/j.jpba.2018.09.029.
   PubMed Web of Science ®Google Scholar
• USP. United States Pharmacopeia, 43th ed.; United States Convention: Rockville, 2020.
   Google Scholar
• Eur. Ph. European Pharmacopoeia, 10th Ed.; Council of Europe: Strasbourg, 2019.
   Google Scholar
• Annapurna, M. M.; Goutam, S.; Pavani, S. New Stability Indicating Liquid Chromatographic Method for the Determination of Rufinamide in Presence of Degradant Products. Drug Invent. Today 2012, 4, 501–506. DOI: 10.5958/0974-360X.2018.00705.9.
   Google Scholar
• Mahamuni, B. S.; Srinivas, R.; Talluri, M. V K. Characterization of Forced Degradation Products of Rufinamide by LC/QTOF/MS/MS, NMR and IR Studies. Anal. Chem. Lett. 2018, 8, 405–415. DOI: 10.1080/22297928.2018.1438315.
   Google Scholar
• Kumar, B. S. P.; Annapurna, M. M.; Pavani, S. Development and Validation of a Stability Indicating RP-HPLC Method for the Determination of Rufinamide. J. Pharm. Anal. 2013, 3, 66–70. DOI: 10.1016/j.jpha.2012.08.003.
   PubMedGoogle Scholar
• Patel, A.; Suhagia, B. N.; Patwari, A. Development and Validation of Stability Indicating HPLC Method for Estimation of Rufinamide in Bulk and Its Pharmaceutical Dosage Form. World J. Pharm. Res. 2014, 3, 1798–1810.
   Google Scholar
• Hassib, S. T.; Hashem, H. M. A.; Mahrouse, M. A.; Mostafa, E. A. Determination of Rufinamide in the Presence of 1-[(2,6-Difluorophenyl)Methyl]-1H-1,2,3-Triazole-4 Carboxylic Acid Using RP-HPLC and Derivative Ratio Methods as Stability Indicating Assays to Be Applied on Dosage Form. J. AOAC Int. 2020, 103, 1–8. DOI: 10.1093/jaoacint/qsaa020.
   PubMed Web of Science ®Google Scholar
• Annapurna, M. M.; Kumar, B. S. P.; Goutam, S.; Srinivas, L. Stability Indicating Liquid Chromatographic Method for the Quantitative Determination of Rufinamide in Pharmaceutical Dosage Forms. J. Drug Deliv. Ther. 2012, 2, 167–174. DOI: 10.22270/jddt.v3i3.498.
   Google Scholar
• Ngumo, P.; Abuga, K. O.; Njogu, P. M.; Ongarora, D. S. B. A Stability Indicating Liquid Chromatography Method for the Assay of Rufinamide Bulk Material and Tablets. East Cent. African J. Pharm. Sci. 2016, 19, 16–21. DOI: 10.1017/CBO9781107415324.004.
   Google Scholar
• Snyder, J. K. Introduction to Modern Liquid Chromatography, John Wiley and Sons, New York, 2011.
   Google Scholar
• Ranjith, K.; Rao, M.; Murthy, T. Development and Validation of Related Substances Method for Rufinamide Tablets by RP-HPLC. J. Chem. Pharm. Res. 2017, 4, 306–314. DOI: 10.26420/austinjanalpharmchemg.2017.1087.
   Google Scholar
• Geetha, M.; Sait, S.; Sripal Reddy, P. A Stability Indicating UPLC Method for the Estimation of Related Substances, Assay and Dissolution of Rufinamide. Asian J. Chem. 2013, 25, 9775–9778. DOI: 10.14233/ajchem.2013.15314.
   Google Scholar
• Patel, A.; Patwari, A.; Suhagia, B. Development of a Validated Stability-Indicating HPTLC Method for Rufinamide in Bulk and Its Pharmaceutical Dosage Form. J. Chromatogr. Sci. 2014, 52, 1294–1301. DOI: 10.1093/chromsci/bmt171.
   PubMed Web of Science ®Google Scholar
• Darwish, H. W.; Abdelhameed, A. S.; Attia, M. I.; Bakheit, A. H.; Khalil, N. Y.; Al-Majed, A. A. A. A Stability-Indicating HPLC-DAD Method for Determination of Stiripentol: Development, Validation, Kinetics, Structure Elucidation and Application to Commercial Dosage Form. J Anal Methods Chem. 2014, 2014, 638910–638951. DOI: 10.1155/2014/638951.
   Web of Science ®Google Scholar
• Shah, S.; Vasantharaju, S. G.; Karthik, A.; Muddukrishna, B. S. Development and Validation of Stability-Indicating Assay Method for Lacosamide by RP- HPLC. Elixir Int. J. 2011, 38, 4174–4177.
   Google Scholar
• Sreenivasulu, V.; Rao, D. R.; Maheswari, B. N. U.; Das, S. K.; Krishnaiah, A. Development and Validation of a Stabiliting-Indicating RP-HPLC Method for Determination of Lacosamide. Res. J. Pharm. Biol. Chem. Sci. 2011, 2, 1–11.
   Google Scholar
• Chhalotiya, U. K.; Bhatt, K. K.; Shah, D. A.; Baldania, S. L.; Patel, J. R. Stability-Indicating Liquid Chromatographic Method for Quantification of New anti-Epileptic Drug Lacosamide in Bulk and Pharmaceutical Formulation. CI&CEQ. 2012, 18, 35–42. DOI: 10.2298/CICEQ110821044C.
   Google Scholar
• Chakravarthy, V. K.; Sankar, D. G. Stability Indicating Hplc Method for Determination of Lacosamide and Its Degradants/Impurities in Bulk and Pharmaceutical Formulation. Rasayan J. Chem. 2012, 5, 293–310.
   Google Scholar
• Patil, S. N.; Agrawal, P. N.; Kadam, A.; Manish, M.; Askshay, S. Development and Validation of Stability Indicating RP-HPLC Method for Estimation of Lacosamide in Bulk and Its Pharmaceutical Formulations. Int. J. Pharm. Sci. Rev. Res. 2014, 28, 164–168.
   Google Scholar
• Tiwari, R. N.; Bonde, C. G. Identification and Characterization of Degradation Products of Lacosamide by Liquid-Chromatography/Time-of-Flight Mass Spectrometric and Multi-Stage Mass Spectrometric Analysis. J. Liq. Chromatogr. Relat. Technol. 2014, 37, 2046–2061. DOI: 10.1080/10826076.2013.825860.
   Web of Science ®Google Scholar
• Ramisetti, N. R.; Kuntamukkala, R.; Lakshetti, S.; Sripadi, P. Identification and Characterization of Stress Degradants of Lacosamide by LC-MS and ESI-Q-TOF-MS/MS: Development and Validation of a Stability Indicating RP-HPLC Method. J. Pharm. Biomed. Anal. 2014, 95, 256–264. DOI: 10.1016/j.jpba.2014.03.010.
   PubMed Web of Science ®Google Scholar
• Mahesh, H. R. K.; Babu, S. K. Quantitative Estimation of Related Compounds of Lacosamide in Oral Solution by Using Reverse Phase HPLC. Der Pharm. Lett. 2015, 7, 285–291.
   Google Scholar
• Kalyan Chakravarthy, V.; Gowri Shankar, D. HPLC Method for Determination of Lacosamide S(-)Enantiomer in Bulk and Pharmaceutical Formulation. Rasayan J. Chem. 2011, 4, 744–752.
   Google Scholar
• Parmar, M.; Nimavat, K.; Vyas, K.; Rao, D.; Pande, R. A Stability-Indicating Liquid Chromatographic Method for the Quantification of New anti-Epileptic Drug Lacosamide and Its Intermediates. Int. J. Pharm. Res. Sch. 2012, 1, 40–47.
   Google Scholar
• Charagondla, K. A Validated Chiral Liquid Chromatographic Method for the Enantiomeric Separation of Lacosamide Drug Product and Its Dosage Forms. J. Chromatogr. Sep. Tech 2015, 06, 1–9. DOI: 10.4172/2157-7064.1000280.
   Google Scholar
• Zhou, N.; Li, T.; Ai, L.; Guo, C.; Zhang, J.; Fu, S.; Wang, Q. Identification of Forced Degradation Products of Lacosamide by LC-QQLIT-MS and LC-IT/TOF-MS. Acta Chromatogr. 2019, 31, 12–18. DOI: 10.1556/1326.2018.00279.
   Web of Science ®Google Scholar
• Molleti, S.; Rao, V.; Jayaveera, K. N. Stability Indicating RP-UPLC Method for the Determination of Lacosamide and Its Impurities in Bulk Drugs and Its Pharmaceutical Dosage Forms. Der. Pharma. Chem. 2013, 5, 81–89.
   Google Scholar
• Patel, A.; Suhagia, B. N.; Patwari, A. Stability Indicating Assay Method for Quantification of Lacosamide in Bulk and Its Pharmaceutical Dosage Form and Characterization of Major Degradation Products. Int. J. Pharm. Pharm. Sci. 2013, 6, 593–599.
   Google Scholar
• Korany, M. A.; Mahgoub, H.; Haggag, R. S.; Ragab, M. A. A.; Elmallah, O. A. Green Gas Chromatographic Stability-Indicating Method for the Determination of Lacosamide in Tablets. Application to in-Vivo Human Urine Profiling. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2018, 1083, 75–85. DOI: 10.1016/j.jchromb.2018.02.033.
   PubMed Web of Science ®Google Scholar
• Mone, M. K.; Chandrasekhar, K. B. Development of Liquid Chromatographic Enantiomer Separation Methods and Validation for the Estimation of (R)-Enantiomer in Eslicarbazepine Acetate. J. Pharm. Biomed. Anal. 2011, 54, 248–251. DOI: 10.1016/j.jpba.2010.08.015.
   PubMed Web of Science ®Google Scholar
• Thomas, S.; Bharti, A.; Maddhesia, P. K.; Shandilya, S.; Agarwal, A.; Dharamvir; Biswas, S.; Bhansal, V.; Gupta, A. K.; Tewari, P. K.; Mathela, C. S. Highly Efficient, Selective, Sensitive and Stability Indicating RP-HPLC-UV Method for the Quantitative Determination of Potential Impurities and Characterization of Four Novel Impurities in Eslicarbazepine Acetate Active Pharmaceutical Ingredient by LC/ES. J. Pharm. Biomed. Anal. 2012, 61, 165–175. DOI: 10.1016/j.jpba.2011.11.024.
   PubMed Web of Science ®Google Scholar
• Thomas, S.; Paul, S. K.; Joshi, S. C.; Kumar, V.; Agarwal, A.; Vir, D. Vir, D. Identification, Synthesis and Characterization of an Unknown Process Related Impurity in Eslicarbazepine Acetate Active Pharmaceutical Ingredient by LC/ESI-IT/MS, 1H, 13C and 1H-1H COSY NMR. J. Pharm. Anal. 2014, 4, 339–344. DOI: 10.1016/j.jpha.2013.08.004.
   PubMedGoogle Scholar
• Srinivas, M.; Avupati, N. R.; Sait, S.; Mukkanti, K. Stability Indicating HPLC Method for the Determination of Eslicarbazepine Acetate and Its Impurities in Bulk Drugs and Pharmaceutical Dosage Forms. J. Liq. Chromatogr. Relat. Technol. 2012, 35, 1550–1564. DOI: 10.1080/10826076.2011.619043.
   Web of Science ®Google Scholar
• Kallam, S. R.; Srikanth, J.; Prakash, K. V. Development and Validation of an RP-HPLC Method for Related Substance and Quantitative Estimation of Eslicarbazepine Acetate in Bulk Drug and Pharmaceutical Dosage Form. J. Pharm. Biol. Sci. 2015, 10, 155–162. DOI: 10.9790/3008-1062155162.
   Google Scholar
• Iram, F.; Alam, P.; Siddiqui, N. A.; Alqasoumi, S. I.; Siddiqui, A. A.; Khan, S. A.; Husain, A. Development of a Stress Induced Validated UPLC-PDA Method for the Analysis of Eslicarbazepine Acetate. Saudi Pharm J 2018, 26, 286–291. DOI: 10.1016/j.jsps.2017.11.009.
   PubMed Web of Science ®Google Scholar
• Patel, C. J.; Patel, S. S.; Patel, M. M. Method Development and Stability Study by Chromatographic Method for Perampanel in API and Tablet Dosage Form. Int. J. Pharm. Drug Anal. 2017, 5, 229–240.
   Google Scholar
• Xia, Y.-Y.; Zou, Q.-G.; Yang, Y.-F.; Sun, Q.; Han, C.-Q. Determination of Impurities in Perampanel Bulk Drugs by High-Performance Liquid Chromatography and Gas Chromatography. Curr. Pharm. Anal. 2020, 16, 1–12. DOI: 10.2174/1573412916999200513105657.
   Google Scholar
• Annapurna, M. M.; Kaibada, R.; Srinivas, M. New Stability Indicating Rp-Ultra Fast Liquid Chromatographic Method for the Determination of Perampanel–an Antiepileptic Drug. Rese. J. Pharm. Technol. 2019, 12, 2657–2663. DOI: 10.5958/0974-360X.2019.00444.X.
   Google Scholar
• Saida, S. J.; Muthuchamy, M.; Kaliyaperumal, M.; Rumalla, S.; Yanaka, R.; Rao, S. Isolation and Spectral Characterization of Degradation Impurity in Perampanel Drug Substance Using UPLC-MS and NMR Spectroscopy: Validation of Assay Method by UPLC. Asian J. Chem. 2018, 30, 2215–2219. DOI: 10.14233/ajchem.2018.21405.
   Google Scholar
• Mali, N. V.; Mhaske, D. V. HPLC Studies on Degradation Behavior of Brivaracetam and Development of Validated Stability – Indicating HPLC Assay Method. IJSRM Human 2016, 4, 43–57.
   Google Scholar
• Bhamare, P.; Umadoss, P.; Upmanyu, N.; Dubey, R. Identification, Isolation, Structural Characterisation, Synthesis and in-Silico Toxicity Prediction of Alkaline Hydrolytic Degradation Product of Brivaracetam by Using LC-PDA, Preparative HPLC, LC/HESI/LTQ, FTIR, 1H NMR. Anal. Methods 2020, 12, 1868–1881. DOI: 10.1039/C9AY02582K.
   Web of Science ®Google Scholar
• Vishweshwar, V.; Babu, J. M.; Muralikrishna, R.; Pharmaceutical, C.; Pradesh, A. Development and Validation of Stability-Indicating Uplc Method for the Determination of Brivaracetam, Its Related Impurities and Degradation Products. Int. J. Pharm. Sci. Res. 2018, 9, 2315–2327. DOI: 10.13040/IJPSR.0975-8232.9(6).2315-27.
   Web of Science ®Google Scholar
• Baksam, V.; Saritha, N.; Pocha, V. R.; Chakka, V. B.; Ummadi, R. R.; Kumar, P. Development of an Effective Novel Validated Stability-Indicating HPLC Method for the Resolution of Brivaracetam Stereoisomeric Impurities. Chirality 2020, 32, 1208–1212. DOI: 10.1002/chir.23269.
   PubMed Web of Science ®Google Scholar
• Sharmila, D.; Rao Lakshmana, A.; Kalyani, L. Development and Validation of Stability-Indicating High Performance Liquid Chromatographic Method for the Estimation of Everolimus in Tablets. Indian J. Pharm. Sci. 2015, 77, 599–604. DOI: 10.4103/0250-474x.169044.
   PubMed Web of Science ®Google Scholar
• Prasad, S. S.; Krishna Mohan, G. V.; Naga Babu, A. Development of Simple and Robust RP-HPLC Method for Determination of Everolimus and Its Impurities in Oral Solid Dosage Form. Asian J. Chem. 2019, 31, 1002–1008. DOI: 10.14233/ajchem.2019.21723.
   Google Scholar
• Kumaraswamy, G.; Lalitha, R.; Vijaypraksh, K. Method Development and Validation for Estimation of Rufinamide in Tablet Dosage Forms by RP-HPLC. Int. J. Pharma. Chem. Anal. 2016, 3, 99. DOI: 10.5958/2394-2797.2016.00015.0.
   Google Scholar
• Parashar, V.; Todkar, M.; Shaikh, F.; Reddy, S.; Mehra, V.; Sinha, S. Validated Liquid Chromatographic Method for Quantitative Determination of Rufinamide Active Pharmaceutical Ingredient Form and Its Impurities. Pharm. Methods 2013, 4, 6–10. DOI: 10.1016/j.phme.2013.08.001.
   Google Scholar
• Mohamed, F. A.; Bakr, M. F.; Rageh, A. H.; Mostafa, A. M. The Use of Separation Techniques in the Analysis of Some Antiepileptic Drugs: A Critical Review. J. Liq. Chromatogr. Relat. Technol. 2016, 39, 783–798. DOI: 10.1080/10826076.2016.1266654.
   Web of Science ®Google Scholar
• Valarmathi, R.; Banu, S. F.; Akilandeswari, S.; Senthamarai, R.; Dhivya, C. S. A Review on New Antiepileptic Drug – Lacosamide and Its Analytical Methods. Int. J. Pharm. Chem. Sci. 2013, 2, 181–186.
   Google Scholar
• Mali, N. V.; Bansode, D. A. Stability Indicating Thin-Layer Chromatographic Determination of Eslicarbazepine Acetate as Bulk Drug: Application to Forced Degradation Study. Der Pharm. Lett. 2016, 8, 38–47.
   Google Scholar
• Narayanam, M.; Sahu, A.; Singh, S. Use of LC-MS/TOF, LC-MS(n), NMR and LC-NMR in characterization of stress degradation products: Application to cilazapril. J. Pharm. Biomed. Anal. 2015, 111, 190–203. DOI: 10.1016/j.jpba.2015.03.038.
   PubMed Web of Science ®Google Scholar